跳至主要內容
HR+/HER2- mBC Online Consensus
搜尋
Treatment Algorithm
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Treatment Algorithm
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Consensus Statements
Risk Evaluation and Biomarker Testing (I)
Risk Evaluation and Biomarker Testing (II)
Selection of First-Line Treatment (I)
Selection of First-Line Treatment (II)
Selection of Second-Line Treatment(I)
Selection of Second-Line Treatment (II)
Non-Endocrine Based Approaches(I)
Non-Endocrine Based Approaches (II)
Consensus Statements
Risk Evaluation and Biomarker Testing (I)
Risk Evaluation and Biomarker Testing (II)
Selection of First-Line Treatment (I)
Selection of First-Line Treatment (II)
Selection of Second-Line Treatment(I)
Selection of Second-Line Treatment (II)
Non-Endocrine Based Approaches(I)
Non-Endocrine Based Approaches (II)
Treatment Algorithm
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Treatment Algorithm
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Consensus Statements
Risk Evaluation and Biomarker Testing (I)
Risk Evaluation and Biomarker Testing (II)
Selection of First-Line Treatment (I)
Selection of First-Line Treatment (II)
Selection of Second-Line Treatment(I)
Selection of Second-Line Treatment (II)
Non-Endocrine Based Approaches(I)
Non-Endocrine Based Approaches (II)
Consensus Statements
Risk Evaluation and Biomarker Testing (I)
Risk Evaluation and Biomarker Testing (II)
Selection of First-Line Treatment (I)
Selection of First-Line Treatment (II)
Selection of Second-Line Treatment(I)
Selection of Second-Line Treatment (II)
Non-Endocrine Based Approaches(I)
Non-Endocrine Based Approaches (II)
HR+/HER2–: Endocrine Refractory
Endocrine refractory/Not a candidate for ET
Investigational therapy
Biomarker-guided therapy
ADC
PARPi
(2025 UPDATE)
